Use of mitochondrial activity inhibitors for the treatment of acute myeloid leukemia with poor prognosis

摘要

Administering an effective amount of a mitochondrial activity inhibitor such as a Class A electron transport chain (ETC) complex I inhibitor, such as miglitinib or a pharmaceutically acceptable salt thereof, to a subject in need thereof to treat acute myelogenous A method for treating leukemia (AML) is disclosed. AML to be treated may be characterized by certain characteristics such as high levels of expression of one or more homeobox (HOX) -network genes, high and / or low expression of a particular gene, one or more cytogenetic or molecular risk factors, ( NK ), mutated NPM1 , mutated CEBPA , mutated FLT3 , mutated DNMT3A , mutated TET2 , mutated IDH1 , mutated IDH2 , mutated RUNX1 , mutated WT1 , mutated SRSF2 , abnormal karyotypes Characterized by the presence of a high frequency of intermediate cytogenetic hazards with interferon (abnK), trichomonic 8 (+8) and / or abnormal chromosome 5/7, and / or leukemia stem cells (LSC) .